Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

EMA panel backs Novo Nordisk’s hemophilia B drug

Written by: | no-reply@reuters.com | Dated: Friday, March 24th, 2017

 

A panel of the European Medicines Agency said it recommended granting marketing approval to Danish drugmaker Novo Nordisk’s hemophilia B drug.

The Committee for Medicinal Products for Human Use gave a positive opinion on the drug, Refixia, intended for the treatment and prevention of bleeding in patients 12 years and above with hemophilia B. bit.ly/2n1edgs

Hemophilia B is caused by the deficiency of the factor IX gene that is instrumental in blood clotting.

The panel’s opinion will now be reviewed by the EMA.

The positive recommendation comes at a time when Novo Nordisk struggles with declining sales from its aging diabetes franchise.

Last month, the Danish group warned that sales and profits might actually slip in 2017, a remarkable change in fortune for a company that was previously renowned for its sector-beating growth.

Outside diabetes, Novo Nordisk already has a significant blood products business focused on hemophilia.

 

(Reporting by Rahul B in Bengaluru; Editing by Anil D’Silva)

 

Reuters source:

http://www.reuters.com/article/us-novo-nordisk-drug-idUSKBN16V1JC

 

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2017 Focus: Manufacturer of the Year, Top 50 Pharma, HBA and more!

Subscribe

Ad Right Bottom

Main Navigation